Multiple sclerosis is a chronic disease that affects each person differently, with symptoms ranging from numbness in the limbs or forgetfulness to paralysis or loss of vision. MS is caused when the body’s immune system attacks the central nervous system, damaging the myelin sheath – the protective layer covering the nerves that carry signals between the brain and spinal cord and the rest of the body.
For over a decade, Sanofi Genzyme has been working to develop novel treatments for MS. Sanofi Genzyme currently has an MS franchise with two products.
We continue to focus our research and development efforts in areas where we believe we have the strongest potential to help the community. These include early-stage programs that focus on preventing and repairing the damage to the nervous system caused by MS.
Drawing on our vast experience in rare diseases, we recognize that truly personalized medicine involves developing relationships with patients and caregivers, health care providers, and disease organizations and foundations.
Though MS affects a much larger population than lysosomal storage disorders, we have built our MS business unit on the same core principle that guides our Rare Disease franchise: the importance of deeply understanding the experiences, challenges, and triumphs of those affected by MS. Since the launch of our MS portfolio in 2011, we’ve cultivated close relationships with the MS community, applying Sanofi Genzyme’s strong patient support and physician engagement models to this patient population.
Last Updated: 10/13/2016